MAbs are hottest segment of biotech industry

The next frontier for big pharma...BD 

Looking for the hottest segment of the biotech industry? Then take a look at monoclonal antibodies (mAbs). A new Datamonitor report projects 14 percent annual growth in the market for the antibody drugs, which mimic the body's own immune system. That's by far the fastest-growing segment of the industry. MAbs currently generate global revenues of around $20 billion and include such  blockbusters as Avastin, Herceptin, Remicade, Rituxan, Humira and Erbitux.

MAbs are hottest segment of biotech industry - FierceBiotech

Related stories:  http://www.fiercebiotech.com/story/stromedix-gets-25m-for-mab-work/2008-04-21?utm_medium=rss&utm_source=rss&cmp-id=OTC-RSS-FB

http://www.fiercebiotech.com/special-reports/emerging-drug-developer-aileron-therapeutics